Pharmicell
파미셀 · 005690
Information Technology Components · KOSPI
Market cap US$606.6M (₩837.1B)
Overview
Pharmicell is a South Korean biopharmaceutical company listed on KOSPI, best known for developing the world's first approved stem-cell therapy for heart-attack patients.
Its Biomedical division develops stem-cell treatments, stores adult stem cells for clients, and supplies cosmetics containing stem-cell culture extracts. Its Biochemical division produces specialty chemicals including electronic materials with low dielectric properties, pharmaceutical intermediates such as Nucleoside and mPEG, and eco-friendly flame retardants for textiles and electronics, and this division accounts for the large majority of the company's total revenue.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$40.7M
- FY2024US$47M
- FY2025US$82.7M
Operating profit
- FY2023US$939.1K
- FY2024US$3.4M
- FY2025US$24.9M
Net income
- FY2023US$2.6M
- FY2024US$4.6M
- FY2025US$29.2M
Key ratios (FY2025)
Why it matters
The Biochemical division was created after Pharmicell absorbed a precision-chemicals subsidiary through a merger, making it an unusual hybrid of biopharma and specialty chemicals under one roof.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?